<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03400826</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00149869</org_study_id>
    <nct_id>NCT03400826</nct_id>
  </id_info>
  <brief_title>Effects of Simvastatin on Uterine Leiomyoma Size</brief_title>
  <official_title>A Double-blinded, Phase II, Randomized Control Trial to Study the Effects of Simvastatin in Patients With Uterine Leiomyoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to study the effect of simvastatin on the size of uterine fibroids.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a phase II double blinded clinical trial to determine feasibility, safety and
      preliminary clinical efficacy of simvastatin to reduce leiomyoma size. Women with symptomatic
      fibroids planned to undergo surgical management for fibroids such as hysterectomy or
      myomectomy will be screened for participation. The eligible women will undergo pre-study
      evaluation to ascertain study eligibility.The study will enroll 60 participants in total,
      half will receive simvastatin and the other half will receive a placebo. The study drug and
      placebo will be an add on to the participants ongoing medical management of fibroids until
      surgery. The participants will be monitored at intervals for the effect of the drug on
      fibroid size and symptoms using ultrasound and quality of life questionnaires.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Tumor size volume pre and post study intervention</measure>
    <time_frame>Change from baseline to 12 weeks post intervention</time_frame>
    <description>Tumor size measured by ultrasound imaging comparing tumor volume using ultrasound imaging. The volume will be reported in Centimeter cubes. The largest radius of the tumor will be used to calculate the volume, this will be measured in centimeters.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical symptom improvement as determined by the Uterine Fibroid Symptom and Health Related Quality of Life Questionnaire.</measure>
    <time_frame>At visit 1 (Screening), At visit 2 (start of the study drug intake), visit 3 (6 weeks after start of the study drug), visit 4( 12 weeks after start of the study drug), and follow up visit at 2 and 6 weeks post hysterectomy</time_frame>
    <description>The questionnaire used is the Uterine Fibroid Symptom and Health Related Quality of Life Questionnaire. This questionnaire is an effective and validated tool for detecting differences in symptom severity and health-related quality of life among patients with uterine fibroids. The scale for this questionnaire denotes symptom severity with lowest and highest possible scores of 8 and 40 respectively. Higher scores indicate greater severity of symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to the recommended treatment dosing</measure>
    <time_frame>At Visit 3 (6 weeks after start of study drug), and Visit 4 (12 weeks after start of the study drug)</time_frame>
    <description>Based on review of patient diaries and counting of left over medications bought back by the subject. This will be reported as an overall percentage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject retention</measure>
    <time_frame>At visit 2 (start of the study drug intake), visit 3 (6 weeks after start of the study drug), visit 4 (12 weeks after start of the study drug), and follow up visit at 2 and 6 weeks post hysterectomy.</time_frame>
    <description>Based on presence at follow up visits to the study site. This will be determined as a simple percentage of subjects that stay in the study until the last visit.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse events reporting by organ systems</measure>
    <time_frame>At visit 2 (start of the study drug intake), visit 3 (6 weeks after start of the study drug), visit 4 (12 weeks after start of the study drug), and follow up visit at 2 and 6 weeks post hysterectomy.</time_frame>
    <description>Based on patient reporting and study team evaluation utilizing CTCAE v.4</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Fibroid Uterus</condition>
  <condition>Fibroid Tumor</condition>
  <condition>Leiomyoma</condition>
  <condition>Fibromyoma</condition>
  <condition>Leiomyoma, Uterine</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The 30 participants randomized in this group will intake Simvastatin 40mg / day of orally at the same time in the evening, every day for the study duration of 12 weeks prior to undergoing hysterectomy/ myomectomy. The fibroid samples will be collected after the surgery to evaluate the effects of the study medication on the fibroid tissue.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The 30 participants randomized in this group will intake Placebo 40mg / day orally at the same time in the evening every day for the study duration of 12 weeks prior to undergoing hysterectomy/ myomectomy. The fibroid samples will be collected after the surgery to evaluate the effects of the study medication on the fibroid tissue.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin 40mg</intervention_name>
    <description>The Treatment Group subjects will orally intake encapsulated Simvastatin 40 mg tablets daily for the 12 weeks duration with water in the evening.</description>
    <arm_group_label>Treatment Group</arm_group_label>
    <other_name>Simvastatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 40 mg</intervention_name>
    <description>The Placebo group will orally intake encapsulated Starch 1500, 40 mg Placebo for 12 weeks duration with water in the evening.</description>
    <arm_group_label>Placebo Group</arm_group_label>
    <other_name>Starch 1500 encapsulated</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed written consent.

          -  Gender: female.

          -  Age: 18-55 years at time of signing consent.

          -  BMI of subjects: &lt; 45 kg/m2.

          -  Uterine fibroids:

          -  Diagnosed by ultrasound (MRI will be used only if ultrasound is inconclusive).

          -  Number: any number of fibroids.

          -  Location: submucosal or intramural.

          -  At least one fibroid of diameter &gt; 3cm.

          -  Symptoms: one or more of the following symptoms of heavy menstrual bleeding (HMB),
             defined as: Experienced cyclic (22 to 35 days) abnormal uterine bleeding (heavy or
             prolonged) in at least 3 of the last 6 menstrual periods, including menstrual bleeding
             lasting 5 or more days or heavy bleeding per participant recall. Examples of heavy
             bleeding may include, but are not limited to the following:

          -  Requires the use of double protection to manage menstrual bleeding.

          -  Menstrual bleeding accompanied by the sensation of &quot;gushing&quot; or &quot;flooding&quot;.

          -  Saturates more than 1 tampon or sanitary pad per hour for 3 or more consecutive hours.

          -  Regularly needs to change the tampon or sanitary pad at night or regularly soils
             bedclothes.

          -  Heavy bleeding that affects work, school, or social activities.

          -  Pelvic pain/ pressure likely caused by fibroids.

          -  Plan for surgery (hysterectomy or myomectomy).

          -  Normal Pap smear within the last year.

          -  Use of contraception during study such as non-hormonal oral contraceptives,
             intrauterine devices (IUD)/ intrauterine systems (IUS), barrier contraceptives,
             abstinence or sterilization.

        Exclusion Criteria:

          -  Pregnancy or lactation.

          -  Previous or current uterine, cervical or ovarian cancer.

          -  Current endometrial hyperplasia or history of atypical endometrial hyperplasia.
             Endometrial biopsy will be done during screening (if not done within last 12 months).

          -  Suspicion of leiomyosarcoma.

          -  Recent rapid growth of fibroids (i.e. doubling in size within 1-6 months period).

          -  Unevaluated gynecologic abnormalities (unexplained vaginal bleeding, cervical
             dysplasia, or abnormal adnexal/ovarian mass).

          -  Menopausal status.

          -  Surgery is urgently indicated (&lt; 3 months) for medical or social reasons.

          -  Hemoglobin â‰¤ 6 g/dL.

          -  Currently enrolled in another investigational study.

          -  Mental condition or other barrier preventing informed written consent.

          -  Allergy or hypersensitivity to simvastatin.

          -  Current use of simvastatin or other drugs of the same class.

          -  Concomitant administration of strong CYP3A4 inhibitors including itraconazole,
             ketoconazole, posaconazole, voriconazole, erythromycin, clarithromycin, telithromycin,
             HIV protease inhibitors, boceprevir, telaprevir, nefazodone, and cobicistat-containing
             products.

          -  Concomitant administration of gemfibrozil, cyclosporine, or danazol, verapamil,
             diltiazem, amiodarone, diltiazem, dronedarone, amlodipine, ranolazine, lomitapide, and
             grapefruit juice.

          -  Active liver disease, which may include unexplained persistent elevations in hepatic
             transaminase levels.( elevation of aspartate transaminase and/or alanine transaminase
             &gt; 2 s.d. above the normal range at screening visit)

          -  Known increased risk or diagnosis of a myopathy.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mostafa Borahay, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johsn Hopkins School Of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mostafa Borahay, MD, PhD</last_name>
    <phone>(410) 550-0337</phone>
    <email>mboraha1@jhmi.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mostafa Borahay, MD, PhD</last_name>
      <phone>410-550-0337</phone>
      <email>mboraha1@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>James Segars, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gayane Yenokyan, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul Driggers, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bhuchitra Singh, MBBS,MPH,MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2018</study_first_submitted>
  <study_first_submitted_qc>January 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 17, 2018</study_first_posted>
  <last_update_submitted>May 23, 2018</last_update_submitted>
  <last_update_submitted_qc>May 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>simvastatin</keyword>
  <keyword>fibroids</keyword>
  <keyword>medical management</keyword>
  <keyword>uterine fibroids</keyword>
  <keyword>leiomyoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

